metastatic breast cancer
FDA Approves Truqap With Fulvestrant for Breast Cancer
The FDA approved capivasertib with fulvestrant for adults with HR-positive, HER2-negative locally advanced or ...
NOVEMBER 17, 2023
Orserdu Approved for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
The FDA has approved Orserdu for postmenopausal women or adult men with estrogen receptor (ER)-positive, ...
FEBRUARY 5, 2023
Kisqali Approved as First-Line Therapy for HR+/HER2-Metastatic Breast Cancer
Kisqali is a selective CDK4/6 inhibitor, a class of drugs that help slow the progression of cancer by inhibiting ...
MARCH 14, 2017
Load more